Evolution of drug regulations and regulatory innovation for anticancer drugs in China
Over the past two decades, China has introduced significant changes to drug regulations through regulatory innovations to accelerate drug review and approvals, keeping in line with the rapidly growing scientific innovation in drug research and development (R&D). In this study, we outlined the re...
Saved in:
Main Authors: | Yang Liu (Author), Ning Zhang (Author), Cuicui Xie (Author), Yale Jiang (Author), Yunhe Qin (Author), Liyun Zhou (Author), Yi Fan (Author), Lianjie Ren (Author), Chen Yin (Author), Huan Yang (Author), Wei Xie (Author), Qing Zhai (Author), Guanqiao Li (Author), Hongzhuan Chen (Author), Xiaoyuan Chen (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2022-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Drug discovery in China: A snapshot of recent progress
by: Hongxi Hu, et al.
Published: (2022) -
Systemic Evaluation on the Pharmacokinetics of Platinum-Based Anticancer Drugs From Animal to Cell Level: Based on Total Platinum and Intact Drugs
by: Zhiying Qin, et al.
Published: (2020) -
Historical evolution of traditional medicine in Japan
by: Gensheng Zhu, et al.
Published: (2019) -
Anticancer therapy-induced adverse drug reactions in children and preventive and control measures
by: Hui Yan, et al.
Published: (2024) -
MicroRNA as an Important Target for Anticancer Drug Development
by: Zhiwen Fu, et al.
Published: (2021)